Form 4: IDEAYA CFO Granted 170,000 Stock Options

IDEAYA Biosciences' Chief Financial Officer, Joshua Bleharski, was granted 170,000 stock options with a vesting schedule over four years.

Summary

• Joshua Bleharski, Chief Financial Officer of IDEAYA Biosciences, Inc. (IDYA), was granted 170,000 stock options.
• The stock options have an exercise price of $32.19 per share.
• The vesting schedule commences on January 1, 2026, with 25% of the shares vesting on the first anniversary of this date.
• Following the initial vesting, 1/48th of the total number of shares will vest monthly thereafter.
• All 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date (January 1, 2030).
• The stock options are set to expire on January 30, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns the CFO's financial incentives with the company's long-term stock performance.

Positives

• The grant of 170,000 stock options to the Chief Financial Officer aligns management's long-term interests with shareholder value.
• The significant number of options provides a substantial incentive for the CFO to contribute to the company's sustained growth and stock performance.

Future Outlook

The grant of long-term equity incentives to the Chief Financial Officer suggests a strategic focus on future performance and the retention of key management. The defined vesting schedule ties the CFO's compensation directly to the company's stock performance over the next four years, encouraging sustained value creation.

Industry Context

StockSavvy.ai notes that granting stock options is a common and established practice within the biotechnology and pharmaceutical industries for executive compensation. This mechanism is widely used to incentivize long-term value creation, retain critical talent, and align the interests of management with those of shareholders in a highly competitive sector.

Comparison to Industry Standards

• Equity compensation, including stock options, is a standard component of executive pay packages across the biotech industry, comparable to practices at companies like Amgen or Gilead Sciences, which frequently use long-term incentives to attract and retain top talent.
• The four-year vesting schedule for these options is typical for executive stock option grants, similar to those observed at peer companies such as Vertex Pharmaceuticals or Regeneron Pharmaceuticals, ensuring sustained commitment from leadership.

Related Party Transactions

• Grant of 170,000 stock options to Joshua Bleharski, the Chief Financial Officer, as part of his executive compensation package.

Stakeholder Impact

• Shareholders: Potential for increased long-term value creation due to aligned management incentives, balanced against potential future dilution if options are exercised.
• Employees: May signal stability in executive leadership and a commitment to long-term company growth and success.

Next Steps

• Continued vesting of stock options according to the defined schedule, with 25% vesting on January 1, 2027, and monthly thereafter until January 1, 2030.
• Potential exercise of options by Joshua Bleharski upon vesting and favorable stock price movement.

Key Dates

Recommendation

The grant of stock options to the CFO is a standard practice for executive compensation, aligning management's long-term interests with shareholder value. While positive for governance and retention, it does not present new operational or financial information that would significantly alter the investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

IDEAYA Biosciences, IDYA, Stock Options, CFO, Joshua Bleharski, Insider Transaction, Equity Compensation, Vesting Schedule